Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ONO-4059

Known as: BTK Inhibitor ONO-4059, Bruton's Tyrosine Kinase Inhibitor ONO-4059 
An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Recent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical… Expand
  • figure 1
  • table 1
2019
2019
AIMS Despite widespread use of dual antiplatelet therapy in acute myocardial infarction, there remains a residual risk of… Expand
  • table 1
  • figure 1
  • figure 2
2014
2014
Introduction Bruton’s tyrosine kinase (BTK) is a critical kinase involved in B-cell receptor signal transduction. ONO-4059, a… Expand
2014
2014
Drug developers are mounting a poly(ADPribose) polymerase (PARP) inhibitor comeback, and a few are now experimenting with a more… Expand
2014
2014
8553 Background: Bruton’s tyrosine kinase (BTK) is a critical kinase involved in B-cell receptor signal transduction. ONO-4059, a… Expand
2013
2013
Introduction The B-cell receptor (BCR) pathway plays a central role in signal transduction pathways that regulate survival… Expand
2013
2013
Purpose Bruton’s tyrosine kinase (Btk) is a key regulator of the B-cell receptor (BCR) signaling pathway and abberant BCR… Expand
2013
2013
Introduction The B-cell receptor (BCR) pathway plays a central role in signal transduction pathways that regulate survival… Expand
2013
2013
Purpose: The B-cell receptor (BCR) pathway plays a central role in signal transduction pathways that regulate survival… Expand